查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402027

2030 年肺炎检测市场预测：按产品类型、测试类型、测试方法、技术、最终用户和地区进行的全球分析

Pneumonia Testing Market Forecasts to 2030 - Global Analysis By Product Type, Type, Test Type, Method, Technology, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球肺炎检测市场规模为 6.5513 亿美元，预计到 2030 年将达到 11.2277 亿美元，预测期内复合年增长率为 8.0%。

一种称为肺炎测试的重要诊断程序用于确定是否存在肺炎（一种导致肺部气囊发炎的呼吸道感染疾病）。肺炎通常由细菌、病毒和真菌引起。如果不治疗，可能会出现严重的呼吸问题。胸部 X 光检查可用于检查肺部是否异常，血液检查可用于确定是否有感染，分析呼吸道分泌物可确定原因。

根据美国美国卫生研究院 (NIH) 2022 年发表的论文，肺炎球菌占美国肺炎病例的 15.0%，全球整体肺炎病例的 27.0%。

人口高龄化与传染病风险

推动肺炎检测市场的关键因素之一是人口结构向高龄化社会的变化。老年人更容易受到包括肺炎在内的呼吸道感染疾病，这增加了准确检测方法的需求。此外，这个人口因素凸显了市场对早期发现和满足高龄化人口独特的医疗保健需求的责任。

尖端诊断系统的初期成本较高

肺炎检测​​市场的一个障碍是与先进诊断技术相关的初期成本。较新的设备，例如先进的影像技术和分子诊断，可能具有较高的初期成本。此外，它可能会减缓这些尖端测试技术的市场渗透并限制其采用，特别是在资源有限的医疗保健环境中。

多重测试平台开发

肺炎检测​​市场的开拓将由可同时检测多种病原体的多重检测平台的发展所推动。透过在单次测试中提供完整的诊断资料并加快诊断过程，这些平台提高了生产效率。此外，检测合併感染和提高整体诊断准确性是多重检测特别有用的两个领域。

卫生系统的财政限制

先进肺炎检测技术的普及受到卫生系统预算限制的威胁。资金有限可能导致难以投资培训卫生工作者和购买尖端诊断工具。此外，这可能会导致无法平等地获得最先进的检测技术，并损害肺炎诊断的整体有效性。

COVID-19 的影响：

COVID-19 大流行改变了医疗保健行业的动态和优先事项，对肺炎检测市场产生了重大影响。随着疫情提高了人们对呼吸系统健康的兴趣以及对诊断解决方案的需求激增，肺炎检测的创新正在加速。另一方面，供应链中断、医疗支出波动以及高峰时期对侦测资源的巨大需求等挑战也构成了巨大的障碍。此外，这场大流行凸显了可扩展且有效的肺炎检测在全球突发卫生事件中发挥的关键作用，迫使该行业进行创新并适应感染疾病不断变化的性质。

预计预测期内病毒性肺炎领域规模最大

就肺炎检测的市场占有率而言，病毒性肺炎细分市场预计将占据最大占有率。由于流感和呼吸道融合细胞病毒（RSV）等呼吸道病毒的爆发，以及以新型冠状病毒SARS-CoV-2 为主要原因的 COVID-19 大流行，病毒性肺炎受到关注。对病毒性肺炎专门诊断解决方案的需求不断增加，导致分子测定、抗原测试和其他诊断技术的进步。此外，呼吸道病毒的传染性以及准确快速检测的需求使该领域成为肺炎检测市场的重点。

诊断实验室部门预计在预测期内复合年增长率最高

在肺炎检测市场中，诊断实验室部门预计将以最高的复合年增长率成长。诊断实验室提供影像检查、血液检查、分子诊断等多种诊断工具，对于提供全面、专业的肺炎检测服务至关重要。由于诊断技术的进步以及对快速、准确的肺炎检测的需求不断增长，诊断检测设施不断发展。此外，这些设施采用最先进的诊断技术，并且通常配备精良，可以有效地处理大量测试。

占有率最大的地区：

预计北美地区将占据肺炎检测的最大市场占有率。该地区的优势在于其强大的医疗基础设施、最先进的诊断技术以及对感染疾病的积极控制。此外，有利的报销政策、意识的提高以及北美呼吸道感染疾病的高盛行率也推动了对肺炎检测的需求。

复合年增长率最高的地区：

预计亚太地区肺炎检测市场的复合年增长率最高。这是由于亚太国家呼吸道感染疾病上升、人口高龄化、卫生基础设施支出增加以及越来越重视加强医疗保健服务。此外，该地区的经济成长、医疗技术的进步以及公众对早期诊断价值的认识不断提高正在推动高成长。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肺炎检测市场：依产品类型

  • 介绍
  • 消耗品及试剂
  • 装置
  • 分析仪
  • 其他产品类型

第六章全球肺炎检测市场：依类型

  • 介绍
  • 链球菌
  • 退伍军人菌
  • 衣原体
  • 病毒性肺炎
  • 霉浆菌肺炎
  • 其他类型

第七章全球肺炎检测市场：依检测类型

  • 介绍
  • 验血
  • 影像检查
  • 痰测试
  • 尿液检查
  • 其他测试类型

第八章全球肺炎检测市场：依方法分类

  • 介绍
  • 分子诊断
  • 即时检测
  • 免疫诊断
  • 其他方法

第九章全球肺炎检测市场：依技术分类

  • 介绍
  • 酵素免疫吸附测定
  • 萤光
  • 西方墨点法
  • 聚合酶炼式反应
  • 免疫组织化学
  • 其他技术

第十章 全球肺炎检测市场：依最终用户分类

  • 介绍
  • 医院和诊所
  • 诊断实验室
  • 居家医疗
  • 其他最终用户

第十一章 全球肺炎检测市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • Danaher
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Beckton and Dickinson Company
  • Cepheid
  • Biomerieux SA
  • Hologic Inc
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Bio Rad laboratories
  • OpGen
  • Quidel Corporation
  • AdvanDx
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter
  • Siemens Healthcare GmbH
  • Quest Diagnostics Incorporated
Product Code: SMRC24547

According to Stratistics MRC, the Global Pneumonia Testing Market is accounted for $655.13 million in 2023 and is expected to reach $1122.77 million by 2030 growing at a CAGR of 8.0% during the forecast period. A vital diagnostic procedure called pneumonia testing is used to determine whether pneumonia-a respiratory infection that inflames the lungs' air sacs-is present. Pneumonia is frequently caused by bacteria, viruses, or fungi. If treatment is not received, it can result in severe respiratory distress. Chest X-rays can be used to see abnormalities in the lungs; blood tests can determine whether an infection is present; and respiratory secretion analysis can pinpoint the cause.

According to a published article by the National Institutes of Health (NIH) in 2022, streptococcus pneumoniae accounts for up to 15.0% of pneumonia cases in the U.S. and 27.0% globally.

Market Dynamics:

Driver:

Population aging and contagious disease risk

One major factor driving the market for pneumonia testing is the demographic shift towards an aging population. There is an increased need for accurate testing procedures because elderly people are more vulnerable to respiratory infections, including pneumonia. Moreover, this demographic factor highlights early detection and the market's responsibility to meet the unique healthcare needs of the aging population.

Restraint:

High initial expenses for cutting-edge diagnostic systems

A barrier to the market for pneumonia testing is the upfront expenses linked to sophisticated diagnostic technologies. Modern instruments like sophisticated imaging technology and molecular diagnostics can be highly expensive up front. Additionally, this could slow down the market penetration of these cutting-edge testing techniques and restrict their adoption, especially in healthcare settings with limited resources.

Opportunity:

Development of platforms for multiplex testing

Pneumonia testing market opportunities are presented by the development of multiplex testing platforms, which can detect multiple pathogens simultaneously. By delivering thorough diagnostic data in a single test and expediting the diagnostic procedure, these platforms increase productivity. Furthermore, discovering co-infections and enhancing overall diagnostic accuracy are two areas in which multiplex testing is especially helpful.

Threat:

Financial limitations in healthcare systems

The widespread adoption of advanced pneumonia testing technologies is threatened by budgetary constraints in healthcare systems. Limited funds may make it more difficult to invest in healthcare personnel's training and to purchase cutting-edge diagnostic tools. Moreover, this may result in unequal access to cutting-edge testing techniques, which could compromise the overall efficacy of pneumonia diagnosis.

COVID-19 Impact:

The COVID-19 pandemic has changed dynamics and priorities in the healthcare sector, which has had a significant effect on the market for pneumonia tests. Pneumonia testing innovation has accelerated due to the pandemic's increased focus on respiratory health and the pressing need for diagnostic solutions. On the other hand, difficulties like supply chain disruptions, fluctuating healthcare spending, and the tremendous demand for testing resources at peak times have also presented formidable obstacles. Additionally, the pandemic has brought to light the critical role that scalable and effective pneumonia testing plays in international health emergencies, and this has forced the industry to innovate and adapt to the changing nature of infectious diseases.

The Viral Pneumonia segment is expected to be the largest during the forecast period

In terms of market share for pneumonia tests, the viral pneumonia segment is projected to hold the largest share. Viral pneumonia has received a lot of attention because of the prevalence of respiratory viruses like influenza and respiratory syncytial virus (RSV) as well as the COVID-19 pandemic, which was primarily caused by the novel coronavirus SARS-CoV-2. Molecular assays, antigen tests, and other diagnostic techniques have advanced as a result of the growth in demand for viral pneumonia-specific diagnostic solutions. Moreover, this segment has become a crucial focal point in the pneumonia testing market due to the contagious nature of respiratory viruses and the need for accurate and quick testing.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

In the market for pneumonia testing, the diagnostic laboratory segment is anticipated to grow at the highest CAGR. Diagnostic laboratories, which provide a variety of diagnostic modalities like imaging studies, blood tests, and molecular diagnostics, are essential to the provision of thorough and specialized testing services for pneumonia. Diagnostic laboratories have grown as a result of improvements in diagnostic technologies and the growing need for quick and accurate testing for pneumonia. Additionally, these facilities are frequently at the forefront of adopting cutting-edge diagnostic techniques and are outfitted to efficiently handle a high volume of tests.

Region with largest share:

The region of North America is projected to have the largest market share for pneumonia testing. The region's prominence is attributed to its strong healthcare infrastructure, cutting-edge diagnostic technologies, and proactive management of infectious diseases. Furthermore, the demand for pneumonia testing is driven by favorable reimbursement policies, heightened awareness, and a higher prevalence of respiratory infections in North America.

Region with highest CAGR:

In the market for pneumonia testing, the Asia-Pacific region is projected to have the highest CAGR. The rising incidence of respiratory infections, the aging population, the increased spending on healthcare infrastructure, and the increased emphasis on enhancing healthcare accessibility in Asia-Pacific nations are some of the causes of this. Moreover, the high growth is a result of the region's growing economies, improvements in healthcare technologies, and increased public awareness of the value of early diagnosis.

Key players in the market:

Some of the key players in Pneumonia Testing market include Danaher , Abbott, F. Hoffmann-La Roche Ltd., Beckton and Dickinson Company, Cepheid, Biomerieux SA, Hologic Inc, Luminex Corporation, Meridian Bioscience, Inc., Bio Rad laboratories, OpGen, Quidel Corporation, AdvanDx, Thermo Fisher Scientific Inc., Beckman Coulter , Siemens Healthcare GmbH and Quest Diagnostics Incorporated .

Key Developments:

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In September 2023, Hologic and Bayer today announced an international partnership focused on improving breast cancer detection. The companies teamed up to deliver contrast-enhanced mammography (CEM) solutions across Europe, Canada and Asia Pacific. CEM, a highly sensitive, relatively low-cost breast imaging modality, combines digital mammography with contrast agent administration. It supports breast cancer diagnosis and guides treatment decisions.

In August 2023, Science and medical technology firm Danaher announced Monday that it has entered into an agreement to acquire Abcam, a Cambridge, U.K.-based supplier of antibodies, reagents, biomarkers, and assays. Under the agreement, Danaher will acquire all outstanding Abcam shares for $24 per share in cash, with a total enterprise value of approximately $5.7 billion, including Abcam's assumed debts and net of acquired cash.

Product Types Covered:

  • Consumables & Reagents
  • Instruments
  • Analyzers
  • Other Product Types

Types Covered:

  • Streptococcus
  • Legionella
  • Chlamydophila
  • Viral Pneumonia
  • Mycoplasma Pneumonia
  • Other Types

Test Types Covered:

  • Blood Test
  • Imaging Test
  • Sputum Test
  • Urine Test
  • Other Test Types

Methods Covered:

  • Molecular Diagnostics
  • Point of Care Testing
  • Immunodiagnostics
  • Other Methods

Technologies Covered:

  • Enzyme Linked Immunosorbant Assay
  • Immunofluoroscence
  • Western Blot
  • Polymerase Chain Reaction
  • Imunohistochemistry
  • Other Technologies

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pneumonia Testing Market, By Product Type

  • 5.1 Introduction
  • 5.2 Consumables & Reagents
  • 5.3 Instruments
  • 5.4 Analyzers
  • 5.5 Other Product Types

6 Global Pneumonia Testing Market, By Type

  • 6.1 Introduction
  • 6.2 Streptococcus
  • 6.3 Legionella
  • 6.4 Chlamydophila
  • 6.5 Viral Pneumonia
  • 6.6 Mycoplasma Pneumonia
  • 6.7 Other Types

7 Global Pneumonia Testing Market, By Test Type

  • 7.1 Introduction
  • 7.2 Blood Test
  • 7.3 Imaging Test
  • 7.4 Sputum Test
  • 7.5 Urine Test
  • 7.6 Other Test Types

8 Global Pneumonia Testing Market, By Method

  • 8.1 Introduction
  • 8.2 Molecular Diagnostics
  • 8.3 Point of Care Testing
  • 8.4 Immunodiagnostics
  • 8.5 Other Methods

9 Global Pneumonia Testing Market, By Technology

  • 9.1 Introduction
  • 9.2 Enzyme Linked Immunosorbant Assay
  • 9.3 Immunofluoroscence
  • 9.4 Western Blot
  • 9.5 Polymerase Chain Reaction
  • 9.6 Imunohistochemistry
  • 9.7 Other Technologies

10 Global Pneumonia Testing Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & Clinics
  • 10.3 Diagnostic Laboratories
  • 10.4 Homecare
  • 10.5 Other End Users

11 Global Pneumonia Testing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Danaher
  • 13.2 Abbott
  • 13.3 F. Hoffmann-La Roche Ltd.
  • 13.4 Beckton and Dickinson Company
  • 13.5 Cepheid
  • 13.6 Biomerieux SA
  • 13.7 Hologic Inc
  • 13.8 Luminex Corporation
  • 13.9 Meridian Bioscience, Inc.
  • 13.10 Bio Rad laboratories
  • 13.11 OpGen
  • 13.12 Quidel Corporation
  • 13.13 AdvanDx
  • 13.14 Thermo Fisher Scientific Inc.
  • 13.15 Beckman Coulter
  • 13.16 Siemens Healthcare GmbH
  • 13.17 Quest Diagnostics Incorporated

List of Tables

  • Table 1 Global Pneumonia Testing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pneumonia Testing Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Pneumonia Testing Market Outlook, By Consumables & Reagents (2021-2030) ($MN)
  • Table 4 Global Pneumonia Testing Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 5 Global Pneumonia Testing Market Outlook, By Analyzers (2021-2030) ($MN)
  • Table 6 Global Pneumonia Testing Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 7 Global Pneumonia Testing Market Outlook, By Type (2021-2030) ($MN)
  • Table 8 Global Pneumonia Testing Market Outlook, By Streptococcus (2021-2030) ($MN)
  • Table 9 Global Pneumonia Testing Market Outlook, By Legionella (2021-2030) ($MN)
  • Table 10 Global Pneumonia Testing Market Outlook, By Chlamydophila (2021-2030) ($MN)
  • Table 11 Global Pneumonia Testing Market Outlook, By Viral Pneumonia (2021-2030) ($MN)
  • Table 12 Global Pneumonia Testing Market Outlook, By Mycoplasma Pneumonia (2021-2030) ($MN)
  • Table 13 Global Pneumonia Testing Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 14 Global Pneumonia Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 15 Global Pneumonia Testing Market Outlook, By Blood Test (2021-2030) ($MN)
  • Table 16 Global Pneumonia Testing Market Outlook, By Imaging Test (2021-2030) ($MN)
  • Table 17 Global Pneumonia Testing Market Outlook, By Sputum Test (2021-2030) ($MN)
  • Table 18 Global Pneumonia Testing Market Outlook, By Urine Test (2021-2030) ($MN)
  • Table 19 Global Pneumonia Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 20 Global Pneumonia Testing Market Outlook, By Method (2021-2030) ($MN)
  • Table 21 Global Pneumonia Testing Market Outlook, By Molecular Diagnostics (2021-2030) ($MN)
  • Table 22 Global Pneumonia Testing Market Outlook, By Point of Care Testing (2021-2030) ($MN)
  • Table 23 Global Pneumonia Testing Market Outlook, By Immunodiagnostics (2021-2030) ($MN)
  • Table 24 Global Pneumonia Testing Market Outlook, By Other Methods (2021-2030) ($MN)
  • Table 25 Global Pneumonia Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 26 Global Pneumonia Testing Market Outlook, By Enzyme Linked Immunosorbant Assay (2021-2030) ($MN)
  • Table 27 Global Pneumonia Testing Market Outlook, By Immunofluoroscence (2021-2030) ($MN)
  • Table 28 Global Pneumonia Testing Market Outlook, By Western Blot (2021-2030) ($MN)
  • Table 29 Global Pneumonia Testing Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
  • Table 30 Global Pneumonia Testing Market Outlook, By Imunohistochemistry (2021-2030) ($MN)
  • Table 31 Global Pneumonia Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 32 Global Pneumonia Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 Global Pneumonia Testing Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 34 Global Pneumonia Testing Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 35 Global Pneumonia Testing Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 36 Global Pneumonia Testing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.